Sonosine

About:

A deep-tech firm set to dramatically improve clinical decision making with an advanced world-class medical imaging device

Website: http://www.sonosine.com/

Twitter/X: sonosine

Description:

At Sonosine, we put the patient and the clinician at the heart of our journey. We are introducing dramatic improvements to clinical decision making with our new world-class medical imaging diagnostic tool, the Pulsar 1. We are a deep-tech company made up of specialists from business, industry and academia and our aim is to contribute to human welfare around the world, including those in hard to reach communities and less developed countries. Step by step we are doing this by introducing to medical specialists never seen before technology. We know that this will dramatically improve the way that they can work with their patients. The Pulsar 1 is a medical imaging diagnostic device that uses patented Electro Magnetic Acoustic (EMA) imaging technology. It makes high-quality medical diagnostics quicker, safer and more comfortable for patients, while providing clinicians with reliable images that enable the best decision making. With roots in the UK science base, as a spin out from the University of Oxford, at Sonosine we are committed to drawing on our deep technical and industrial expertise to change the way clinicians diagnose and treat their patients in primary care settings. The Pulsar 1 will enable them to do this effectively, removing the need for medical imaging centre referrals and invasive and costly medical imaging processes.

Total Funding Amount:

2.25M GBP

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Oxford, Oxfordshire, United Kingdom

Founded Date:

2015-10-01

Contact Email:

info(AT)sonosine.com

Founders:

David Edwards

Number of Employees:

1-10

Last Funding Date:

2020-10-02

IPO Status:

Private

Industries:

© 2025 bioDAO.ai